Claims for Patent: 9,655,946

Summary for Patent: 9,655,946

Title:	Daptomycin formulations and uses thereof
Abstract:	Lyophilized daptomycin formulations having improved reconstitution times are provided. The lyophilized daptomycin formulations include an additive, which can be a pharmaceutically acceptable antioxidant, a pharmaceutically acceptable organic acid or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable glucose derivative or a pharmaceutically acceptable salt thereof, or a combination thereof. Also provided are methods of methods of preparing the lyophilized daptomycin formulations, and methods of treating bacterial infections and treating or preventing biofilms by using the lyophilized daptomycin formulations.
Inventor(s):	Alexiou; Jim (Oakleigh East, AU), Knill; Andrew (Bittern, AU), Norris; Noel (Endeavour Hills, AU), Whittaker; Darryl (Vermont, AU)
Assignee:	HOSPIRA AUSTRALIA PTY LTD. (Victoria, AU)
Application Number:	14/427,618
Patent Claims:	1. A lyophilized daptomycin formulation comprising a lyophilizate of an aqueous solution of daptomycin and an additive selected from the group consisting of pharmaceutically acceptable organic acids and pharmaceutically acceptable salts thereof, acetyl glucosamine, and combinations thereof, wherein the pharmaceutically acceptable organic acids and pharmaceutically acceptable salts thereof, if present, have a concentration of from 10 mM to 500 mM in the aqueous solution prior to lyophilization. 2. The lyophilized daptomycin formulation of claim 1, wherein the formulation comprises from about 200 mg to about 600 mg of daptomycin. 3. The lyophilized daptomycin formulation of claim 1, wherein the pharmaceutically acceptable organic acid is selected from the group consisting of monocarboxylic organic acids, dicarboxylic organic acids, hydroxyl substituted dicarboxylic organic acids, tricarboxylic organic acids, hydroxyl substituted tricarboxylic organic acids, tetracarboxylic organic acids, and combinations thereof. 4. The lyophilized daptomycin formulation of claim 3, wherein the pharmaceutically acceptable organic acid is a hydroxyl substituted tricarboxylic organic acid. 5. The lyophilized daptomycin formulation of claim 4, wherein the hydroxyl substituted tricarboxylic organic acid is citric acid. 6. A reconstituted daptomycin formulation comprising the lyophilized daptomycin formulation of claim 1, wherein the lyophilized formulation is reconstituted in a pharmaceutically acceptable diluent to obtain the reconstituted daptomycin formulation. 7. The reconstituted daptomycin formulation of claim 6, wherein the lyophilized formulation is reconstituted in the pharmaceutically acceptable diluent in less than about 5 minutes. 8. The reconstituted daptomycin formulation of claim 6, wherein the concentration of daptomycin in the reconstituted daptomycin formulation is from about 20 mg/mL to about 100 mg/mL. 9. The reconstituted daptomycin formulation of claim 6, wherein the concentration of the additive in the reconstituted daptomycin formulation is from about 1 mM to about 500 mM. 10. The reconstituted daptomycin formulation of claim 9, wherein the concentration of the additive in the reconstituted daptomycin formulation is about 237.5 mM. 11. The reconstituted daptomycin formulation of claim 9, wherein the concentration of the additive in the reconstituted daptomycin formulation is about 300 mM. 12. The reconstituted daptomycin formulation of claim 6, wherein the concentration of the additive in the reconstituted daptomycin formulation is from about 1 mg/mL to about 500 mg/mL. 13. The reconstituted daptomycin formulation of claim 6, wherein the pH of the reconstituted daptomycin formulation is from about 4.0 to about 5.0. 14. The reconstituted daptomycin formulation of claim 13, wherein the pH of the reconstituted daptomycin formulation is about 4.7. 15. The reconstituted daptomycin formulation of claim 6, wherein the diluent is selected from the group consisting of sterile water for injection, bacteriostatic water for injection, 0.45% sodium chloride solution for injection, 0.9% sodium chloride solution for injection, Ringer's solution, lactated Ringer's solution, and combinations thereof. 16. The reconstituted daptomycin formulation of claim 15, wherein the diluent is 0.9% sterile sodium chloride solution for injection. 17. The reconstituted daptomycin formulation of claim 15, wherein the diluent is sterile water for injection. 18. A method of treating a bacterial infection in a subject, comprising administering to the subject an effective amount of a reconstituted daptomycin formulation of claim 6. 19. A method of treating a biofilm, the method comprising exposing a surface of a device to a solution comprising an effective amount of a reconstituted daptomycin formulation of claim 6. 20. A method for preparing a lyophilized daptomycin formulation of claim 1, wherein the method comprises: (a) forming an aqueous solution of daptomycin and an additive, which is selected from the group consisting of pharmaceutically acceptable organic acids and pharmaceutically acceptable salts thereof, acetyl glucosamine, and combinations thereof, wherein the pharmaceutically acceptable organic acids and pharmaceutically acceptable salts thereof, if present, have a concentration of from 10 mM to 500 mM in the aqueous solution; (b) adjusting the pH to from about 4.0 to about 5.0; and (c) lyophilizing the solution to obtain a lyophilizate. 21. A method for preparing a lyophilized daptomycin formulation of claim 1, wherein the method comprises: (a) forming an aqueous solution of daptomycin at a pH of from about 4.0 to 5.0; (b) dissolving an additive selected from the group consisting of pharmaceutically acceptable organic acids, pharmaceutically acceptable salts thereof and acetyl glucosamine in the aqueous solution of the daptomycin, wherein the pharmaceutically acceptable organic acids and pharmaceutically acceptable salts thereof, if present, have a concentration of from 10 mM to 500 mM in the aqueous solution; (c) adjusting the pH to from about 4.0 to about 5.0; and (d) lyophilising lyophilizing the solution to obtain a powder.

Details for Patent 9,655,946

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2032-09-11